Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer

References

• HundahlSAFlemingIDFremgenAMMenckHRA national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995Cancer19988312263826489874472
   PubMed Web of Science ®Google Scholar
• MartinsRGRajendranJGCapellPByrdDRMankoffDAMedullary thyroid cancer: options for systemic therapy of metastatic disease?J Clin Oncol200624111653165516549818
   PubMed Web of Science ®Google Scholar
• EliseiRCosciBRomeiCPrognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up studyJ Clin Endocrinol Metab200893368268718073307
   PubMed Web of Science ®Google Scholar
• LodishMBStratakisCARET oncogene in MEN2, MEN2B, MTC, and other forms of thyroid cancer: molecular genetics and therapeutic advanceExpert Rev Anticancer Ther20088462563218402529
   PubMed Web of Science ®Google Scholar
• PrazeresHTorresJRodriguesFHow to treat a signal? Current basis for RET-genotype-oriented choice of kinase inhibitors for the treatment of medullary thyroid cancerJ Thyroid Res2011201167835721765992
   PubMedGoogle Scholar
• MarshDJLearoydDLAndrewSDSomatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomaClin Endocrinol (Oxf)19964432492578729519
   PubMed Web of Science ®Google Scholar
• CarlomagnoFGuidaTAnagantiSDisease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsOncogene200423366056606315184865
   PubMed Web of Science ®Google Scholar
• VerbeekHHAlvesMMde GrootJWThe effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cellsJ Clin Endocrinol Metab2011966E991E99521470995
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor angiogenesisN Engl J Med2008358192039204918463380
   PubMed Web of Science ®Google Scholar
• CappCWajnerSMSiqueiraDRBrasilBAMeurerLMaiaALIncreased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinomaThyroid201020886387120615131
   PubMed Web of Science ®Google Scholar
• BunoneGVigneriPMarianiLExpression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological featuresAm J Pathol199915561967197610595926
   PubMed Web of Science ®Google Scholar
• Pàez-RibesMAllenEHudockJAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell200915322023119249680
   PubMed Web of Science ®Google Scholar
• YouW-KSenninoBWilliamsonCWVEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancerCancer Res201171144758476821613405
   PubMed Web of Science ®Google Scholar
• BussolinoFDi RenzoMFZicheMHepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growthJ Cell Biol199211936296411383237
   PubMed Web of Science ®Google Scholar
• ApplemanLJMET signaling pathway: a rational target for cancer therapyJ Clin Oncol201129364837483822042966
   PubMed Web of Science ®Google Scholar
• Di RenzoMFOliverMGiacominiAOverexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancerClin Cancer Res1995121471549815967
   PubMed Web of Science ®Google Scholar
• PapottiMOliveroMVolanteMExpression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroidEndocr Pathol2000111193012114654
   PubMed Web of Science ®Google Scholar
• ConstantiniFGenetic controls and cellular behaviors in branching morphogenesis of the renal collecting systemWIREs Dev Biol201215693713 Available from: http://dx.org/10.1002/wdev.52Accessed November 12, 2012
   Web of Science ®Google Scholar
• Exelixis IncPress ReleaseExelixis files IND application for anticancer compound XL184 Available from: http://ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-newsArticle&ID=720188&highlight=Accessed September 6, 2012
   Google Scholar
• TorresKEZhuQSBillKActivated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumorsClin Cancer Res201117123943395521540237
   PubMed Web of Science ®Google Scholar
• YakesFMChenJTanJCabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthMol Cancer Ther201110122298230821926191
   PubMed Web of Science ®Google Scholar
• JannePAWaxMLeachJShangkarGEngelmanJTargeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial designEur J Cancer20086552
   Google Scholar
• De GrootJFPradosMUrquhartTA Phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapseJ Clin Oncol20092715 SupplAbstr 2047
   Web of Science ®Google Scholar
• KurzrockRShermaSIBallDWActivity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancerJ Clin Oncol201129192660266621606412
   PubMed Web of Science ®Google Scholar
• Exelixis Available from: http://www.exelixis.com
   Google Scholar
• SchlumbergerMJEliseiRBastholtLPhase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerJ Clin Oncol200927233794380119564535
   PubMed Web of Science ®Google Scholar
• SchoffskiPEliseiRMullerSAn international, double-blind, randomized, placebo-controlled Phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baselineJ Clin Oncol201230SupplAbstr 5508
   Google Scholar
• WellsSAJrRobinsonBGGagelRFVandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialJ Clin Oncol201230213414122025146
   PubMed Web of Science ®Google Scholar
• Rodríguez-AntonaCPallaresJMontero-CondeCOverexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasisEndocr Relat Cancer2012171716
   Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsdomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
   PubMed Web of Science ®Google Scholar
• SpigelDRErvinTJRamlauRFinal efficacy results from OAM4558G, a randomized Phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Oral abstract sessionJ Clin Oncol201129SupplAbstr 7505
   Web of Science ®Google Scholar
• WedgeSROgilvieDJDukesMZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationCancer Res815200262164645465512183421
   PubMed Web of Science ®Google Scholar
• PolverinoACoxonAStarnesCAMG 706, an oral, mulitkinase inhibitor that selectively targets VEGF, PDGF, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenograftsCancer Res91200666178715872116951187
   PubMed Web of Science ®Google Scholar
• MendelDBLairdADXinXIn vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res120039132733712538485
   PubMed Web of Science ®Google Scholar
• Hu-LoweDDZouHYGrazziniMLNonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3Clin Cancer Res1115200814227272728319010843
   PubMed Web of Science ®Google Scholar